Literature DB >> 1864290

Use of quinolones for treatment of ear and eye infections.

M Barza1.   

Abstract

Malignant otitis externa is a severe, necrotizing infection of the external auditory canal which is sometimes fatal. The traditional antimicrobial treatment has usually been the combination of an antipseudomonal beta-lactam and an aminoglycoside, given intravenously for 4 to 8 weeks. Over 100 patients have been treated with a fluoroquinolone alone, most commonly ciprofloxacin given by mouth in a dosage of 750 mg b.i.d. for 6 to 12 weeks. About 90% of patients have been cured. Treatment with a quinolone has the advantage over older treatments that it can be given orally and has a low rate of side-effects. The ocular penetration of the fluoroquinolones has been studied in patients with unifected eyes. After the administration of a single dose of ciprofloxacin, pefloxacin, ofloxacin or norfloxacin, penetration into the aqueous humor, expressed as the ratio of the peak concentration in the aqueous humor to that in the serum, is about 20%. The penetration of ciprofloxacin into the vitreous humor, based primarily on the data from one report, is about 20%. The concentrations are likely to be higher after repeated doses or in the inflamed eye. Whether the concentrations achieved will be adequate for therapeutic or prophylactic purposes has not been determined.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864290     DOI: 10.1007/bf01967003

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  22 in total

1.  Dose response of experimental Pseudomonas endophthalmitis to ciprofloxacin, gentamicin, and imipenem: evidence for resistance to "late" treatment of infections.

Authors:  P G Davey; M Barza; M Stuart
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

2.  Successful treatment of malignant external otitis with oral ciprofloxacin: report of experience with 23 patients.

Authors:  R Lang; S Goshen; R Kitzes-Cohen; J Sadé
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

3.  Aqueous humor penetration of ciprofloxacin in the human eye.

Authors:  A T Skoutelis; S P Gartaganis; C J Chrysanthopoulos; D Beermann; C Papachristou; H P Bassaris
Journal:  Arch Ophthalmol       Date:  1988-03

4.  Ciprofloxacin treatment of malignant external otitis.

Authors:  J Sadé; R Lang; S Goshen; R Kitzes-Cohen
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

5.  Malignant external otitis with multiple cranial nerve involvement.

Authors:  J M Damiani; K K Damiani; S E Kinney
Journal:  Am J Otol       Date:  1979-10

6.  Penetration of ciprofloxacin into aqueous humor.

Authors:  A I Fern; G Sweeney; M Doig; G Lindsay
Journal:  Trans Ophthalmol Soc U K       Date:  1986

7.  Necrotizing external otitis treated with ciprofloxacin. A case report.

Authors:  F Sabater; J Mensa; J Doménech; M Loncá; M Carulla
Journal:  J Laryngol Otol       Date:  1988-07       Impact factor: 1.469

8.  [Intracamera penetration of ofloxacin in man].

Authors:  A Bron; D Talon; B Delbosc; J M Estavoyer; G Kaya; J Royer
Journal:  J Fr Ophtalmol       Date:  1987       Impact factor: 0.818

9.  [Intracameral penetration of pefloxacine in man].

Authors:  A Bron; D Talon; B Delbosc; J M Estavoyer; F Prost; M Montard
Journal:  J Fr Ophtalmol       Date:  1986       Impact factor: 0.818

10.  Prognostic implications of therapy for necrotizing external otitis.

Authors:  J P Corey; R A Levandowski; A P Panwalker
Journal:  Am J Otol       Date:  1985-07
View more
  3 in total

1.  External Otitis: A Challenge in Management.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

2.  Intravitreal penetration of oral pefloxacin in humans.

Authors:  M Oncel; G A Peyman
Journal:  Int Ophthalmol       Date:  1993-08       Impact factor: 2.031

3.  Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach.

Authors:  Damini Sood; Neeraj Kumar; Aarushi Singh; Meena Kishore Sakharkar; Vartika Tomar; Ramesh Chandra
Journal:  Genomics Inform       Date:  2018-09-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.